Effect of YM-14673, a new thyrotropin releasing hormone analogue, on ataxic gait in cytosine arabinoside-treated mice.
The effect of YM-14673, a new thyrotropin releasing hormone (TRH) analogue, on ataxic gait in mice treated with cytosine arabinoside was observed and compared with the effect of TRH. Ataxic gait was observed after administration of cytosine arabinoside in a dose of 40 mg/kg (s.c.) on the second and third postnatal days. The falling index, the ratio of the number of inversions to spontaneous motor activity, is regarded as an index of ataxia. YM-14673 significantly reduced the falling index. YM-14673 was about 30 times more potent than TRH in reducing the ataxic activity. These results suggest that YM-14673 ameliorates the ataxic gait of cytosine arabinoside-treated mice.
Yamamoto
M
M
Department of Pharmacology, Yamanouchi Pharmaceutical Co. Ltd., Ibaraki, Japan.
Shimizu
M
M
D000818:Animals; D000831:Animals, Newborn; D001259:Ataxia / Q000139:chemically induced / Q000188:drug therapy*; D001384:Azetidines / Q000627:therapeutic use*; D001385:Azetines / Q000627:therapeutic use*; D003561:Cytarabine; D004151:Dipeptides / Q000627:therapeutic use*; D005684:Gait; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D009043:Motor Activity / Q000187:drug effects; D013973:Thyrotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use*
D001384:Azetidines; D001385:Azetines; D004151:Dipeptides; D003561:Cytarabine; D013973:Thyrotropin-Releasing Hormone; C054995:azetirelin